K Number
K214040
Date Cleared
2022-04-12

(110 days)

Product Code
Regulation Number
882.4560
Reference & Predicate Devices
Predicate For
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

The ClearPoint® Array System is intended to provide stereotactic guidance for the placement and operation of instruments or devices during planning and operation of neurological procedures within the MRI environment and in conjunction with MR imaging. The ClearPoint ® Array System is intended as an integral part of procedures that have traditionally used stereotactic methodology. These procedures include biopsies, catheter and electrode insertion including deep brain stimulation (DBS) lead placement. The System is intended for use only with 1.5 and 3.0 Tesla MRI scanners and MR Conditional implants and devices.

Device Description

The ClearPoint Array System is comprised of a workstation laptop with workstation software, the SMARTGrid™ MRI-Guided Planning Grid, the SMARTFrame™ Array MRI-Guided Trajectory Frame, SmartFrame Array Reducer Tube Kit, the ClearPoint™ Accessory Kit, the SMARTFrame™ Array Thumb Wheel Extension Set, and the MRI Neuro Procedure Drape.

A pre-alignment may be used when it is desired to obtain an approximate alignment using a Surgical Navigation System prior to performing final alignment and device placement in the MR Scanner using real-time MR Images. Pre-alignment using an SNS is not intended to provide accurate stereotactic placement. The final alignment and insertion must be performed using real-time MR images with ClearPoint Array software prior to inserting a device in the brain. The SMARTGrid™ MRI-Guided Planning Grid and associated Marking Tool are designed to assist the physician to precisely position the entry hole as called out in the trajectory planning software.

The SMARTFrame™ Array MRI-Guided Trajectory Frame is an adjustable trajectory frame that provides the quidance and fixation for neurosurgical tools. MRI visible fluids in the Targeting Stem along with the fiducial markers in the frame allows for trajectory feedback when the physician views the MR images, makes changes and confirms the subsequent MR images. The ClearPoint Array System can be used with any MRI-compatible head fixation frame to immobilize the patient's head with respect to the scanner table, as well as with any imaging coil(s) (supplied by scanner manufacturers) that meet the physician's desired imaging quality. ClearPoint Neuro also supplies an optional head fixation frame that can be used with the ClearPoint Array System.

The ClearPoint System Array Workstation includes the following:

  1. ClearPoint Workstation Software (for trajectory planning and monitoring)
  2. Laptop Computer

The hardware components of the ClearPoint Array System are the SMARTFrame Array and accessories. They are all single use devices that are provided sterile. They include the following:
1 SMARTFrame Array Pack
a. SMARTFrame Array (adjustable trajectory frame to guide and hold the neurosurgical tools, includes Probe Adapter and Tracker Rod)
b. SMARTFrame Array Scalp Mount Base (includes fiducials, titanium screws, and support pins)
c. Entry Point Locator
d. Targeting Stem
e. Centering Device
f. Dock
g. Device Lock (2 different diameters)
h. Screwdriver
i. 2.1-mm Guide Tube
j. 4.5 Center Drill Guide
k. 4.5 Offset Drill Guide
l. 3.4-mm Drill Reducer Tube
m. Center Insertion Guide
n. Offset Insertion Guide
2 SmartFrame Array Thumb Wheel Extension Set for the trajectory frame
3 SmartFrame Array Guide Tube Kit
a. 1.7-mm Guide Tube
b. 2.5-mm Guide Tube and Device Lock
c. 3.2-mm Guide Tube and Device Lock
4 SmartFrame Array Guide Tubes (sold seperately)
a. 7.9mm Center and Offset Device Guides
b. 5.4mm Center and Offset Device Guides

Common components to ClearPoint System include:

  1. SMARTGrid Pack (interacts with the Software to determine the desired location of the burr hole):
    a. Marking Grid
    b. Marking Tool
  2. Accessory pack:
    a. Peel away sheath
    b. Stylet
    c. Depth Stop
    d. Ruler
  3. MRI Neuro Procedure Drape
AI/ML Overview

The provided text, a 510(k) Summary for the ClearPoint Array System (version 1.1), focuses on demonstrating substantial equivalence to a predicate device, primarily due to a software update. While it mentions 'Targeting Accuracy' as an acceptance criterion and states a specific performance, it does not provide a detailed study design as might be found in a clinical trial report.

Here's an attempt to extract and infer the information based on the provided text:

Acceptance Criteria and Reported Device Performance

The key acceptance criterion mentioned, which is related to the device's accuracy, is:

Acceptance CriterionReported Device Performance
Targeting Accuracy≤ 2.0 mm

Study Proving Device Meets Acceptance Criteria

The document states: "The company completed new software validation for the ClearPoint Array version 1.1 software update, which includes the addition of the preoperative planning module."

While this indicates that a validation study was performed, the document does not provide details for many of the requested items (2-9) about the study design, sample size, expert involvement, or ground truth establishment. This is typical for a 510(k) submission showing substantial equivalence, where detailed de novo clinical study results are often not required if the changes are minor and do not raise new questions of safety and effectiveness, and performance is demonstrated through established engineering and software validation principles.

Based on the provided text, the following information is not available:

  1. Sample size used for the test set and the data provenance: Not specified. The document implies software validation was done, but details on the "test set" (e.g., number of image sets, countries of origin, retrospective/prospective) are absent.
  2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts: Not specified.
  3. Adjudication method for the test set: Not specified.
  4. If a multi reader multi case (MRMC) comparative effectiveness study was done, and the effect size of how much human readers improve with AI vs without AI assistance: Not specified. This type of study is typically done for AI/ML-driven diagnostic devices that assist human readers in interpretation. The ClearPoint Array System is a stereotaxic guidance system, and the software update is for a preoperative planning module, rather than a diagnostic AI. Therefore, an MRMC study is unlikely to be relevant or performed for this device.
  5. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done: Not explicitly detailed. The "Targeting Accuracy" metric suggests an objective, standalone measurement of the system's precision, but the methodology for this measurement (e.g., phantom study, cadaver study) is not provided.
  6. The type of ground truth used: Not explicitly stated. For a stereotaxic system, ground truth for accuracy studies would typically involve precise physical measurements on phantoms or cadavers, or comparison to a gold-standard imaging or navigation system. The document does not elaborate on this.
  7. The sample size for the training set: Not applicable based on the information provided. The software update is described as "incorporat[ing] an update" and "new software validation," implying traditional software development and testing, rather than an AI/ML model that requires a "training set" in the machine learning sense. The preoperative planning module might involve algorithms, but the text doesn't suggest a deep learning model requiring a large training dataset.
  8. How the ground truth for the training set was established: Not applicable, as no training set (in the AI/ML context) is mentioned or implied.

In summary, the document provides the acceptance criterion for targeting accuracy (≤ 2.0 mm) and states that the device meets this, but it does not detail the specific study methodology (e.g., sample size, ground truth establishment, expert involvement, or comparative effectiveness studies) beyond "new software validation." This level of detail is usually not included in a 510(k) summary focused on substantial equivalence for a non-AI/ML device where the change is primarily a software update to a planning module.

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health and Human Services logo on the left and the FDA logo on the right. The FDA logo is a blue square with the letters "FDA" in white, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue.

April 12, 2022

ClearPoint Neuro, Inc. % John Smith Partner Hogan Lovells US LLP 555 Thirteenth St. NW Washington, District of Columbia 20004

Re: K214040

Trade/Device Name: ClearPoint Array System (version 1.1) Regulation Number: 21 CFR 882.4560 Regulation Name: Stereotaxic Instrument Regulatory Class: Class II Product Code: HAW Dated: February 11, 2022 Received: February 11, 2022

Dear John Smith:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's

{1}------------------------------------------------

requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Adam D. Pierce, Ph.D. Assistant Director DHT5A: Division of Neurosurgical, Neurointerventional and Neurodiagnostic Devices OHT5: Office of Neurological and Physical Medicine Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K214040

Device Name

ClearPoint Array System (version 1.1)

Indications for Use (Describe)

The ClearPoint Array System is intended to provide stereotactic guidance for the placement and operation of instruments or devices during planning and operation of neurological procedures within the MRI environment and in conjunction with MR imaging. The ClearPoint Array System is intended as an integral part of procedures that have traditionally used stereotactic methodology. These procedures include biopsies, catheter and electrode insertion including deep brain stimulation (DBS) lead placement. The System is intended for use only with 1.5 and 3.0 Tesla MRI scanners and MR Conditional implants and devices.

Type of Use (Select one or both, as applicable)
☒ Prescription Use (Part 21 CFR 801 Subpart D)☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(k) SUMMARY

ClearPoint Neuro Inc.'s ClearPoint Array System (version 1.1)

Submitter's Name, Address, Telephone Number, Contact Person, and Date Prepared:

ClearPoint Neuro Inc. 5 Musick Irvine, CA 92618 Phone: (949) 900-6833 Facsimile: (888) 979-8369 Contact Person: Megan Faulkenberry, VP Quality & Regulatory

Date Prepared: April 12, 2022

Name of Device: ClearPoint Array System (version 1.1)

Common or Usual Name: ClearPoint Array System

Classification Name: Neurological Stereotaxic Instrument, 21 CFR 882.4560

Regulatory Class: Class II

Product Code: HAW

Predicate Device:

ClearPoint Array System (K202575)

Intended Use / Indications for Use

The ClearPoint® Array System is intended to provide stereotactic guidance for the placement and operation of instruments or devices during planning and operation of neurological procedures within the MRI environment and in conjunction with MR imaging. The ClearPoint ® Array System is intended as an integral part of procedures that have traditionally used stereotactic methodology. These procedures include biopsies, catheter and electrode insertion including deep brain stimulation (DBS) lead placement. The System is intended for use only with 1.5 and 3.0 Tesla MRI scanners and MR Conditional implants and devices.

Device Description

The ClearPoint Array System is comprised of a workstation laptop with workstation software, the SMARTGrid™ MRI-Guided Planning Grid, the SMARTFrame™ Array MRI-Guided Trajectory Frame, SmartFrame Array Reducer Tube Kit, the ClearPoint™ Accessory Kit, the SMARTFrame™ Array Thumb Wheel Extension Set, and the MRI Neuro Procedure Drape.

A pre-alignment may be used when it is desired to obtain an approximate alignment using a Surgical Navigation System prior to performing final alignment and device placement in the MR Scanner using real-time MR Images. Pre-alignment using an SNS is not intended to provide accurate stereotactic placement. The final alignment and insertion must be performed

{4}------------------------------------------------

using real-time MR images with ClearPoint Array software prior to inserting a device in the brain. The SMARTGrid™ MRI-Guided Planning Grid and associated Marking Tool are designed to assist the physician to precisely position the entry hole as called out in the trajectory planning software.

The SMARTFrame™ Array MRI-Guided Trajectory Frame is an adjustable trajectory frame that provides the quidance and fixation for neurosurgical tools. MRI visible fluids in the Targeting Stem along with the fiducial markers in the frame allows for trajectory feedback when the physician views the MR images, makes changes and confirms the subsequent MR images. The ClearPoint Array System can be used with any MRI-compatible head fixation frame to immobilize the patient's head with respect to the scanner table, as well as with any imaging coil(s) (supplied by scanner manufacturers) that meet the physician's desired imaging quality. ClearPoint Neuro also supplies an optional head fixation frame that can be used with the ClearPoint Array System.

The ClearPoint System Array Workstation includes the following:

    1. ClearPoint Workstation Software (for trajectory planning and monitoring)
    1. Laptop Computer

The hardware components of the ClearPoint Array System are the SMARTFrame Array and accessories. They are all single use devices that are provided sterile. They include the following:

  • 1 SMARTFrame Array Pack
    • a. SMARTFrame Array (adjustable trajectory frame to guide and hold the neurosurgical tools, includes Probe Adapter and Tracker Rod)
    • b. SMARTFrame Array Scalp Mount Base (includes fiducials, titanium screws, and support pins)
    • c. Entry Point Locator
    • d. Targeting Stem
    • Centering Device e.
    • f. Dock
    • g. Device Lock (2 different diameters)
    • Screwdriver h.
    • i. 2.1-mm Guide Tube
    • j. 4.5 Center Drill Guide
    • 4.5 Offset Drill Guide k.
    • l. 3.4-mm Drill Reducer Tube
    • m. Center Insertion Guide
    • n. Offset Insertion Guide
  • 2 SmartFrame Array Thumb Wheel Extension Set for the trajectory frame
  • 3 SmartFrame Array Guide Tube Kit
    • a. 1.7-mm Guide Tube
    • b. 2.5-mm Guide Tube and Device Lock

{5}------------------------------------------------

  • c. 3.2-mm Guide Tube and Device Lock
  • 4 SmartFrame Array Guide Tubes (sold seperately)
    • a. 7.9mm Center and Offset Device Guides
    • b. 5.4mm Center and Offset Device Guides

Common components to ClearPoint System include:

    1. SMARTGrid Pack (interacts with the Software to determine the desired location of the burr hole):
    • a. Marking Grid
    • b. Marking Tool
    1. Accessory pack:
    • a. Peel away sheath
    • b. Stylet
    • c. Depth Stop
    • d. Ruler
    1. MRI Neuro Procedure Drape

Summary of Technological Characteristics

The purpose of this 510(k) notice is to incorporate an update to the ClearPoint Array software. The updated version of the software includes a preoperative planning module. This optional step in the clinical workflow involves planning one or more trajectory paths into the brain prior to the day of surgery, using previously acquired images of the patient.

{6}------------------------------------------------

Summary of Technological Characteristics of the Device Compared to the Predicate Device

ClearPoint Array System (K202575)ClearPoint Array System (v1.1)(Subject Device)
Classification21 C.F.R. § 882.456021 C.F.R. § 882.4560
Product codeHAWHAW
Intended UseThe ClearPoint® Array System isintended to provide stereotacticguidance for the placement andoperation of instruments or devicesduring planning and operation ofneurological procedures within the MRIenvironment and in conjunction with MRimaging. The ClearPoint® Array Systemis intended as an integral part ofprocedures that have traditionally usedstereotactic methodology. Theseprocedures include biopsies, catheterand electrode insertion including deepbrain stimulation (DBS) lead placement.The System is intended for use onlywith 1.5 and 3.0 Tesla MRI scannersand MR Conditional implants anddevices.The ClearPoint® Array System isintended to provide stereotacticguidance for the placement andoperation of instruments or devicesduring planning and operation ofneurological procedures within the MRIenvironment and in conjunction with MRimaging. The ClearPoint® Array Systemis intended as an integral part ofprocedures that have traditionally usedstereotactic methodology. Theseprocedures include biopsies, catheterand electrode insertion including deepbrain stimulation (DBS) lead placement.The System is intended for use onlywith 1.5 and 3.0 Tesla MRI scannersand MR Conditional implants anddevices.
EnvironmentMRI Suite or ORMRI Suite or OR
SterilizationEO 10-6 SALEO 10-6 SAL
SMARTGrid PackMRI Planning Grid & Marking toolMRI Planning Grid & Marking tool
SMARTFrame PackSMARTFrame Array AdjustableTrajectory Frame, Scalp Mount Base,Entry Point Locator, Targeting Stem,Centering Device, Dock, Device Lock,screwdriver, 2.1-mm Guide Tube,Center Drill Guide, Offset Drill Guide,3.4-mm Drill Reducer Tube, CenterInsertion Guide, Offset Insertion GuideSMARTFrame Array AdjustableTrajectory Frame, Scalp Mount Base,Entry Point Locator, Targeting Stem,Centering Device, Dock, Device Lock,screwdriver, 2.1-mm Guide Tube,Center Drill Guide, Offset Drill Guide,3.4-mm Drill Reducer Tube, CenterInsertion Guide, Offset Insertion Guide
Hand ControllerThumbwheel ExtensionThumbwheel Extension
Accessory packPeel away sheath, Stylet, Depth stop,rulerPeel away sheath, Stylet, Depth stop,ruler
Drill GuidesDrill Guide, 4.5-mm (included inSMARTFrame Pack)Drill Guide, 4.5-mm (included inSMARTFrame Pack)
Targeting Cannula IDNo ID, Targeting Stem is completelyfluid-filledNo ID, Targeting Stem is completelyfluid-filled
Targeting CannulaMaterialPEEKPEEK
Guide Tube/DeviceGuide/Drill Guide IDDrill Guide ID: 4.5 mm (included inSmartFrame Pack)Drill Guide Tube ID: 3.4 mm (included inSmartFrame Pack)Guide Tube ID: 3.2 mmDrill Guide ID: 4.5 mm (included inSmartFrame Pack)Drill Guide Tube ID: 3.4 mm (included inSmartFrame Pack)Guide Tube ID: 3.2 mm
Guide Tube ID: 2.5 mmGuide Tube ID: 2.5 mm
Guide Tube ID: 2.1 mmGuide Tube ID: 2.1 mm
Guide Tube ID: 1.7 mmGuide Tube ID: 1.7 mm
PackagingSMARTFrame Array Pack: PETG Traywith sealed Tyvek Lid inside of a SealedMylar-Tyvek PouchSMARTFrame Array Pack: PETG Traywith sealed Tyvek Lid inside of a SealedMylar-Tyvek Pouch
SMARTFrame Array ThumbwheelExtension: PETG Tray sealed in aDouble Mylar-Tyvek PouchSMARTFrame Array ThumbwheelExtension: PETG Tray sealed in aDouble Mylar-Tyvek Pouch
SMARTFrame Array Guide Tube Kit:Sealed Double Mylar-Tyvek PouchesSMARTFrame Array Guide Tube Kit:Sealed Double Mylar-Tyvek Pouches
Targeting Accuracy≤ 2.0 mm≤ 2.0 mm
SoftwareClearPoint Array 1.0.xClearPoint Array 1.1.x

{7}------------------------------------------------

Substantial Equivalence

The company completed new software validation for the ClearPoint Array version 1.1 software update, which includes the addition of the preoperative planning module.

The ClearPoint Array System has the same intended use and indications for use, similar technological characteristics and principles of operation as the predicate ClearPoint Array System. The addition of the preoperative planning module to the ClearPoint Array software does not raise new and different questions of safety and effectiveness.

Conclusions

The ClearPoint Array System is as safe and effective as the predicate device. The ClearPoint Array System has the same indications for use, technological characteristics, and principles of operation as its predicate device. In addition, the minor technological differences between the subject device and its predicate devices raise no new issues of safety or effectiveness. Thus, the ClearPoint Array System is substantially equivalent to the predicate device.

§ 882.4560 Stereotaxic instrument.

(a)
Identification. A stereotaxic instrument is a device consisting of a rigid frame with a calibrated guide mechanism for precisely positioning probes or other devices within a patient's brain, spinal cord, or other part of the nervous system.(b)
Classification. Class II (performance standards).